 Belgian-based UCB SA OTC: UCBJF has agreed to buy Zogenix Inc NASDAQ: ZGNX, a U.S. maker of drugs to treat seizures and rare diseases, for 1.9 billion, expanding its portfolio to treat epilepsy. Investors will get 26 in cash for every Zogenix share, plus a potential 2 per share payment if Zogenixs Fintepla drug gets regulatory approval for Lennox-Gastaut syndrome by the end of 2023. 